The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 1974, 113: 910-917.
Copyright © 1974 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, B. M.
Right arrow Articles by Colley, D. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Greene, B. M.
Right arrow Articles by Colley, D. G.

Eosinophils and Immune Mechanisms

II. Partial Characterization of the Lymphokine Eosinophil Stimulation Promoter1

Bruce M. Greene2 and Daniel G. Colley3

From the Departments of Medicine and Microbiology, Vanderbilt University, and the Veterans Administration Hospital, Nashville, Tennessee 37232

Abstract

Eosinophil stimulation promoter (ESP) is a soluble product of activated mouse lymphoid cells which increases in vitro migration of mouse eosinophils. Pretreatment of the lymphoid cells, either by freezing and thawing or the lytic action of antithymocyte serum, abolished the ability of these sensitized cells to produce ESP when challenged by specific antigen. Its production is inhibited by the addition of puromycin. ESP is relatively heat stable, with full activity remaining after incubation at 60°C for 30 min, but none after 100°C for 30 min. Dilution markedly reduces its activity. ESP is sensitive to a proteolytic enzyme, chymotrypsin, but insensitive to RNase and to Vibrio cholera neuraminidase. Molecular sieve column chromatography of ESP-containing culture supernatant fluids yields a single peak of ESP activity, associated with only a small fraction of the total protein. The estimated molecular weight of ESP is 24,000 to 56,000 daltons.

Footnotes

1 This study was supported by the Veterans Administration and by United States Public Health Service Grant AI-11289.

2 Veterans Administration Clinical Association.

3 Address reprint requests to Dr. Greene at Veterans Administration Hospital, Nashville, Tennessee 37203.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1974 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1974 by The American Association of Immunologists, Inc. All rights reserved.